The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Role of PI3K Signaling in Survival and Progression of LNCaP Prostate Cancer Cells to the Androgen Refractory State
Abstract
The mechanisms by which prostate cancer (PCa) cells progress to a hormone refractory state are poorly understood. The progression process under androgen ablation conditions involves the survival of at least a portion of malignant cells and their eventual proliferation in an androgen-independent manner. The goal of this study was to investigate the role of PI3K signaling in such a progression. Using an in vitro model of androgen ablation, we show that after removal of androgen support, the human PCa cell line LNCaP initially arrested in G(1) and trans-differentiated into neuroendocrine-like cells that eventually resumed androgen-independent proliferation. Both acute and chronic androgen ablation resulted in an increase in basal levels of PI3K and Akt activity, which were sustained throughout the progression process. Under these conditions, inhibition of PI3K, pharmacologically or with ectopic expression of PTEN, arrested cell proliferation and blocked progression to the androgen-independent state. In contrast, LNCaP cells in the presence of androgens were marginally sensitive to PI3K inhibition. During the chronic stage of androgen deprivation, androgen-independent proliferation correlated with diminished p27(kip1) protein levels, whereas PI3K and Akt activity remained elevated. At this stage, PI3K inhibition rapidly triggered accumulation of p27(kip1), cell cycle arrest, and cell death. PI3K modulated p27(kip1) levels at least in part by regulating its rate of degradation. Taken together, these data show that androgen ablation alone can increase PI3K-Akt activation, which supports survival after acute androgen ablation and proliferation during chronic androgen deprivation. Successful progression to the androgen-independent state in the LNCaP cell line model requires intact PI3K signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Signal Transduction through MAP Kinase Cascades
(1998) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60765-4 · Cited by 1,759
AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1
Medema, R. H., Kops, G. J. P. L., Bos, J. L., & Burgering, B. M. T. (2000) · Nature · doi:10.1038/35008115 · Cited by 1,438
Requirement for Phosphatidylinositol-3 Kinase in the Prevention of Apoptosis by Nerve Growth Factor
Yao, R., & Cooper, G. M. (1995) · Science · doi:10.1126/science.7701324 · Cited by 1,391
Huggins, C., & Hodges, C. V. (1972) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.22.4.232 · Cited by 1,320
Cyclin E-CDK2 is a regulator of p27Kip1.
Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M., & Clurman, B. E. (1997) · Genes & Development · doi:10.1101/gad.11.11.1464 · Cited by 911
Negative Regulation of the Forkhead Transcription Factor FKHR by Akt
Tang, E. D., Nuñez, G., Barr, F. G., & Guan, K.-L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.16741 · Cited by 761
Mechanism of activation and function of protein kinase B
Alessi, D. R., & Cohen, P. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80062-2 · Cited by 743
Regulation of the Cdk inhibitor p27 and its deregulation in cancer
Slingerland, J., & Pagano, M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200004)183:1<10::aid-jcp2>3.0.co;2-i · Cited by 695
Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15587 · Cited by 674
Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5246 · Cited by 639
Nakamura, N., Ramaswamy, S., Vazquez, F., Signoretti, S., Loda, M., & Sellers, W. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.8969-8982.2000 · Cited by 570
The LNCaP cell line--a new model for studies on human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Chu, T. M., Wajsman, Z., Friedman, M., Papsidero, L. D., Kim, U., Chai, L. S., Kakati, S., Arya, S. K., et al. (1980) · PubMed · Cited by 544
Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase
Ahmed, N. N., Grimes, H. L., Bellacosa, A., Chan, T. O., & Tsichlis, P. N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3627 · Cited by 519
(2001) · PubMed · Cited by 500
Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003145200 · Cited by 378
Neuroendocrine differentiation in prostatic carcinoma
Abrahamsson, P.-A. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990501)39:2<135::aid-pros9>3.0.co;2-s · Cited by 370
LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis
Thalmann, G. N., Sikes, R. A., Wu, T. T., Degeorges, A., Chang, S.-M., Ozen, M., Pathak, S., & Chung, L. W. K. (2000) · The Prostate · doi:10.1002/1097-0045(20000701)44:2<91::aid-pros1>3.0.co;2-l · Cited by 366
Davies, M. A., Koul, D., Dhesi, H., Berman, R. S., McDonnell, T. J., McConkey, D. J., Yung, W. K. A., & Steck, P. A. (1999) · PubMed · Cited by 303
Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
Management of Cancer of the Prostate
Wood, A. J. J., & Catalona, W. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410133311507 · Cited by 294
Papandreou, C. N., Usmani, B., Geng, Y., Bogenrieder, T., Freeman, R., Wilk, S., Finstad, C. L., Reuter, V. E., Powell, C. T., Scheinberg, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-050 · Cited by 277
Weng, L.-P. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.6.599 · Cited by 264
Endemann, G., Yonezawa, K., & Roth, R. A. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)40243-3 · Cited by 257
Kokontis, J. M. (1998) · Molecular Endocrinology · doi:10.1210/me.12.7.941 · Cited by 250
Agus, D. B., Cordon-Cardo, C., Fox, W., Drobnjak, M., Koff, A., Golde, D. W., & Scher, H. I. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1869 · Cited by 248
Bang, Y. J., Pirnia, F., Fang, W. G., Kang, W. K., Sartor, O., Whitesell, L., Ha, M. J., Tsokos, M., Sheahan, M. D., & Nguyen, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5330 · Cited by 246
Lin, J., Adam, R. M., Santiestevan, E., & Freeman, M. R. (1999) · PubMed · Cited by 241
Cox, M., Deeble, P. D., Lakhani, S., & Parsons, S. J. (1999) · PubMed · Cited by 224
Mamillapalli, R., Gavrilova, N., Mihaylova, V. T., Tsvetkov, L. M., Wu, H., Zhang, H., & Sun, H. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00065-3 · Cited by 224
Growth factor involvement in progression of prostate cancer
Russell, P. J., Bennett, S., & Stricker, P. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.4.705 · Cited by 216
Knudsen, K. E., Arden, K. C., & Cavenee, W. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20213 · Cited by 204
Montgomery, B. T., Young, C. Y. ‐., Bilhartz, D. L., Andrews, P. E., Thompson, N. F., Tindall, D. J., & Prescott, J. L. (1992) · The Prostate · doi:10.1002/pros.2990210107 · Cited by 178
Carson, J. P., Kulik, G., & Weber, M. J. (1999) · PubMed · Cited by 162
Zhang, M., Magit, D., & Sager, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5673 · Cited by 158
Schneikert, J., Peterziel, H., Defossez, P.-A., Klocker, H., de Launoit, Y., & Cato, A. C. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23907 · Cited by 156
Cheney, I. W., Neuteboom, S., Vaillancourt, M. T., Ramachandra, M., & Bookstein, R. (1999) · PubMed · Cited by 133
Yao, H. W., York, R. D., Misra-Press, A., Carr, D. W., & Stork, P. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.14.8240 · Cited by 130
Li, P., Nicosia, S. V., & Bai, W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010226200 · Cited by 113
Huang, C., Schmid, P. C., Ma, W.-Y., Schmid, H. O., & Dong, Z. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4187 · Cited by 109
Two principles in endocrine therapy of cancers: hormone deprival and hormone interference.
Huggins, C. (1964) · PubMed · Cited by 101
Growth factors and epithelial-stromal interactions in prostate cancer development
Wong, Y. C., & Wang, Y. Z. (2000) · International review of cytology · doi:10.1016/s0074-7696(00)99002-8 · Cited by 99
Molecular Mechanisms of Androgen-Independent Growth of Human Prostate Cancer LNCaP-AI Cells
Lu, S., Tsai, S. Y., & Tsai, M. (1999) · Endocrinology · doi:10.1210/endo.140.11.7086 · Cited by 88
Role of p27 in Prostate Carcinogenesis
Macrì, E., & Loda, M. F. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006133620914 · Cited by 86
Cheng, L., Lloyd, R. V., Weaver, A. L., Pisansky, T. M., Cheville, J. C., Ramnani, D. M., Leibovich, B. C., Blute, M. L., Zincke, H., & Bostwick, D. G. (2000) · PubMed · Cited by 84
MITRA, S. P., & Carraway, R. E. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00064-7 · Cited by 16
Cited by
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402824 · Cited by 1,176
Sphingosine 1-phosphate and cancer
Pyne, N. J., & Pyne, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2875 · Cited by 852
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
Zhuang, L., Kim, J., Adam, R. M., Solomon, K. R., & Freeman, M. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200519935 · Cited by 567
“Consistent with published data that serum withdrawal stimulates Akt activity in LNCaP cells (36), we observed a time-dependent increase in Akt activity and phosphorylation at the 2 principal regulatory sites (T308 and S473) when cells were placed in serum-free conditions (Figure 1B).”
BackgroundDavies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 471
Metadata
- Authors
- Murillo, H.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2001-11-01
- Volume
- 142
- Issue
- 11
- Pages
- 4795-4805
- ISSN
- 0013-7227 (ISSN-L)
- OpenAlex
- W2025288244
- Cited by
- 263
- References
- 52
- FWCI
- 11.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.